| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Division of Cardiology, University of Texas Medical Branch, Galveston, Texas, USA
2 The Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
3 The Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, USA
* To whom correspondence should be addressed. E-mail: yobirnba{at}utmb.edu.
Objectives: We determined the effects of cycloxygenase-1 (COX1)(Sc560), COX2 (Sc58125) and inducible nitric oxide synthase (iNOS)(1400w) inhibitors on atorvastatin (ATV)-induced myocardial protection and whether iNOS mediates the ATV-induced increases in COX2. Methods: Sprague-Dawley rats received ATV 10 mg/kg/d added to the drinking water or water alone for 3 days. Rats received IV Sc58125, Sc560, 1400W or vehicle alone. Anesthesia was induced with ketamine and xylazine and maintained with isofluorane. Fifteen minutes after IV injection rats underwent 30min myocardial ischemia followed by 4h reperfusion [infarct size (IS) protocol], or the hearts were explanted for biochemical analysis and immunoblotting. Results: Left ventricular weight and the area at risk were comparable among groups. ATV reduced IS to 12.7% (SD 3.1%) of AR, a reduction of 64% vs. 35.1% (SD 7.6) in the sham-treated group, P<0.001). Sc58125 and 1400W attenuated the protective effect without affecting IS in the non-ATV treated rats. ATV increased calcium independent NOS (iNOS) (11.9 (SD 0.8) vs. 3.9 (SD 0.1) X 1000cpm; P<0.001) and COX2 (46.7 (SD 1.1) vs. 6.5 (SD 1.4) pg/ml of 6-keto-PGF1
; P<0.001) activity. Both Sc58125 and 1400W attenuated this increase. Sc58125 did not affect iNOS activity, whereas 1400W blocked iNOS activity. COX2 was S-nitrosylated in the ATV-treated but not in the sham-treated rats or rats pretreated with 1400W. COX2 immuno-precipitated with iNOS, but not with eNOS. Conclusions: ATV reduced IS by increasing the activity of iNOS and COX2. iNOS is upstream to COX2. iNOS activates COX2 by S-nitrosylation. These results are consistent with the hypothesis that preconditioning effects are mediated via prostaglandin.
This article has been cited by other articles:
|
|
 |
|
  D. T. Hess, M. W. Foster, and J. S. Stamler Assays for S-Nitrosothiols and S-Nitrosylated Proteins and Mechanistic Insights Into Cardioprotection Circulation, July 21, 2009; 120(3): 190 - 193. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ye, Y. Lin, S. Manickavasagam, J. R. Perez-Polo, B. C. Tieu, and Y. Birnbaum Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2436 - H2446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsumoto, E. Noguchi, K. Ishida, T. Kobayashi, N. Yamada, and K. Kamata Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1165 - H1176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ye, J. D. Martinez, R. J. Perez-Polo, Y. Lin, B. F. Uretsky, and Y. Birnbaum The role of eNOS, iNOS, and NF-{kappa}B in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H343 - H351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Birnbaum, Y. Lin, Y. Ye, R. Merla, J. R. Perez-Polo, and B. F. Uretsky Pretreatment With High-Dose Statin, But Not Low-Dose Statin, Ezetimibe, or the Combination of Low-Dose Statin and Ezetimibe, Limits Infarct Size in the Rat Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2008; 13(1): 72 - 79. [Abstract] [PDF]
|
|
|
|
|
|
H. Sato, R. Bolli, G. D. Rokosh, Q. Bi, S. Dai, G. Shirk, and X.-L. Tang The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2557 - H2564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Merla, Y. Ye, Y. Lin, S. Manickavasagam, M.-H. Huang, R. J. Perez-Polo, B. F. Uretsky, and Y. Birnbaum The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1918 - H1928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ye, Y. Lin, R. Perez-Polo, M.-H. Huang, M. G. Hughes, D. J. McAdoo, S. Manickavasagam, B. F. Uretsky, and Y. Birnbaum Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H813 - H818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Salinas, U. C. Rangasetty, B. F. Uretsky, and Y. Birnbaum The Cycloxygenase 2 (COX-2) Story: It's Time to Explain, Not Inflame Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2007; 12(2): 98 - 111. [Abstract] [PDF]
|
|
|
|
|
|
Y. Birnbaum, Y. Lin, Y. Ye, J. D. Martinez, M.-H. Huang, C. Y. Lui, J. R Perez-Polo, and B. F. Uretsky Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2891 - H2897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ye, Y. Lin, S. Atar, M.-H. Huang, J. R. Perez-Polo, B. F. Uretsky, and Y. Birnbaum Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1158 - H1169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Birnbaum, Y. Ye, Y. Lin, S. Y. Freeberg, S. P. Nishi, J. D. Martinez, M.-H. Huang, B. F. Uretsky, and J. R. Perez-Polo Augmentation of Myocardial Production of 15-Epi-Lipoxin-A4 by Pioglitazone and Atorvastatin in the Rat Circulation, August 29, 2006; 114(9): 929 - 935. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
